"Real-world Study Shows Obesity Medications Lower Multiple Sclerosis Risk"
Real-world data from the FDA suggests that obesity medications, particularly those that activate the GLP-1 receptor and lower blood glucose levels, are associated with a reduced risk of developing multiple sclerosis (MS). The study explored the potential of repurposing these medications for MS treatment, as both conditions share inflammatory components. Medications such as semaglutide, dulaglutide, liraglutide, empagliflozin, and metformin were found to significantly lower the likelihood of developing MS, hinting at the possibility of repurposing anti-diabetic drugs with weight loss-inducing effects for potential MS treatment opportunities.
